科迈迪克斯

最新新闻

• Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD)
  TipRanks · 2026/8/14
• 评级变动
  Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2025/11/13
• Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/1/10
• 评级变动
  Analysts' Top Healthcare Picks: Cormedix (CRMD), CG Oncology, Inc. (CGON)
  TipRanks · 2026/2/4
• 评级变动
  Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/1/9
• RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/4/9
• 评级变动
  Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2025/12/19
• 评级变动
  H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/1/23
• 评级变动
  H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2025/11/13
• 评级变动
  Needham Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/1/9
• 评级变动
  Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating, Announces Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/1/9
• 评级变动
  Needham Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• 评级变动
  Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/4/15
• H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Leerink Partners Maintains CorMedix(CRMD.US) With Buy Rating, Announces Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/3/7
• RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/8/14

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。